
Objective Convergence Insufficiency and Fusional Convergence Amplitude Measurement with an Eye Tracking Based Device
Tamara Wygnanski-Jaffe, M.D; Michael Belkin, M.D; Oren Yehezkel Ph.D
ESA 2019
ESA 2019
Oren Yehezkel, Tamara Wygnanski-Jaffe, Michael Belkin and Avital Moshkovitz
Journal of vision
December 2022
Tamara Wygnanski–Jaffe, Burton J. Kushner, Avital Moshkovitz, Michael Belkin, Oren Yehezkel
Ophthalmology
October 2022
Tsaina Mahlen, Robert W Arnold
Clinical Ophthalmology
February 2022
Leilei Zou, Tian Tian, Tamara Wygnanski-Jaffe, Oren Yehezkel, Shu Wang, Avital Moshkovitz, Xinghuai Sun, Hong Liu and Rui Liu
Seminars in Ophthalmology
November 2021
Oren Yehezkel, Michael Belkin, and Tamara Wygnanski-Jaffe
American Journal of Ophthalmology
May 2020
© 2022 NovaSight | All Rights Reserved | NS-00779-R06
CureSight™ and EyeSwift®PRO devices are CE marked in accordance with EU Medical Device Regulation 2017/745.
CureSight™ is an FDA 510(K) cleared device.
Caution: The EyeSwift®PRO system is an Investigational Device, Limited By Federal (Or United States) Law To Investigational Use.
Currently, TrackSightTM is not approved for sales in any country.
Your data will be handled in accordance with our Privacy
Policy. In the event that a child’s or minor’s information is
being submitted as part of this form, we hereby request
that such information be submitted solely by the legal
guardian of such child or minor.
Your data will be handled in accordance with our Privacy
Policy. In the event that a child’s or minor’s information is
being submitted as part of this form, we hereby request
that such information be submitted solely by the legal
guardian of such child or minor.
This website uses cookies for functional, operational, analytical and advertising purposes. Please review our Privacy Policy for more information